Put companies on watchlist
Cantourage Group SE
ISIN: DE000A3DSV01
WKN: A3DSV0
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Cantourage Group SE · ISIN: DE000A3DSV01 · EQS - Company News (47 News)
Country: Germany · Primary market: Germany · EQS NID: 1776653
20 November 2023 07:30AM

Cantourage Group SE records significant revenue growth in the first nine months of 2023 and confirms full-year forecast


EQS-News: Cantourage Group SE / Key word(s): 9 Month figures
Cantourage Group SE records significant revenue growth in the first nine months of 2023 and confirms full-year forecast

20.11.2023 / 07:30 CET/CEST
The issuer is solely responsible for the content of this announcement.


Not for publication or distribution, directly or indirectly, in or into the United States of America, Australia, Canada or Japan or any other jurisdiction in which such publication or distribution would be unlawful. The important notices at the end of this press release should be observed.

Cantourage Group SE records significant revenue growth in the first nine months of 2023 and confirms full-year forecast

  • Opening of new production facilities expected from December
  • Expansion of purchasing and sales activities

Berlin, 20 November 2023 – In the first nine months of 2023, Cantourage Group SE (hereinafter “Cantourage”, ISIN: DE000A3DSV01, www.cantourage.com/en), a leading European company for the production and distribution of cannabis, recorded revenues of EUR 17.2 million*, which corresponds to a significant increase of 85% compared to the same period of the previous year (previous year: EUR 9.3 million*). In the third quarter of 2023 revenue increased to EUR 6.1 million* (Q3 2022: EUR 3.4 million*).

The operating result (EBITDA) of Cantourage amounted to EUR -0.4 million* in the first nine months of the current financial year (previous year: EUR -1.9 million*) and was therefore still slightly negative. Reasons for the development in the third quarter of 2023 (EBITDA Q3 2023: EUR -0.6 million*; EBITDA Q3 2022: EUR -1.2 million*) were, among other things, delays in the approval of new production facilities.

Cantourage expects significant efficiency gains in a rapidly growing market in the coming years. The first effects are already expected in the fourth quarter of 2023, which is why the company is sticking to its previous forecast of a balanced EBITDA.

In order to take account of the expected development and to position itself even better in the cannabis market, Cantourage focused on optimizing its purchasing and sales activities in recent months. Thus, the Berlin-based company launched its own telemedicine platform for cannabis called Telecan° (www.telecan.eu) to provide potential patients with a simple and direct route to cannabis therapy. In addition, Cantourage signed a long-term supply agreement for cannabis with the Swiss cannabis company Astrasana, marking a significant development for the supply of cannabis in Switzerland with this partnership.

In order to further expand supply to the European cannabis market, Cantourage has also recently started working with two new cultivation partners, SUMO Cannabis and VASCO (both Canada). In addition, there were further product launches with eight new flower varieties from six growers (all in Canada).

The British subsidiary Cantourage UK is also continuing to focus on expanding its presence in the cannabis sector. An exclusive partnership was concluded with the GHA (Gibraltar Healthcare Authority) for the supply of cannabis medicines. Cantourage UK also launched a new product range from craft cannabis cultivator Green Karat.

Cantourage is thus consistently preparing for the further liberalization of the European cannabis market.

Based on the expectations for the current quarter, Cantourage continues to expect to achieve its forecast for the full year 2023. Accordingly, the company continues to expect an increase in revenues in the high double-digit percentage range for the 2023 financial year compared to the previous year (revenue 2022: EUR 14.1 million*) and a break-even result at EBITDA level.

Bernd Fischer, CFO of Cantourage, states: "Our business development was successful in the first nine months of 2023. In addition to the increase in revenue, we were also able to successfully implement our planned milestones for further company development – such as the launch of our own online platform for cannabis on prescription called Telecan°. As a result of this and cost-saving measures, we expect to achieve our forecast business development for 2023 as planned."

 

* The figures stated relate to an unaudited pro forma consolidation of the operating subsidiaries as if they had been acquired as at 1 January of each year.

About Cantourage
Cantourage is a leading European producer and distributor of cannabis-based medicinal preparations and drugs. The Berlin-based company was founded in 2019 by industry pioneers Norman Ruchholtz, Dr. Florian Holzapfel and Patrick Hoffmann. With an experienced management team and its “Fast Track Access” platform, Cantourage enables producers from around the world to become part of the growing European medical cannabis market faster, easier and more cost-effectively by processing and distributing their cannabis raw materials and extracts. In this context, Cantourage ensures compliance with the highest European pharmaceutical quality standards at all times. The company offers pharmaceutical-grade products in all relevant market segments: dried flower, extracts, dronabinol and cannabidiol. Cantourage was listed on the Frankfurt Stock Exchange on 11 November 2022 and is listed under ticker symbol “HIGH”.

For further information: www.cantourage.com/en

This announcement does not constitute a public offer or an advertisement for a public offer for sale of securities, in particular within the meaning of Regulation (EU) 2017/1129 (Prospectus Regulation).

Press contact at Cantourage:
Stefanie Frey
Tel. +49 (0)30 4701 350 - 50
frey@cantourage.com



20.11.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Cantourage Group SE
Feurigstraße 54
10827 Berlin
Germany
E-mail: info@cantourage.com
Internet: https://www.cantourage.com/
ISIN: DE000A3DSV01
WKN: A3DSV0
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1776653

 
End of News EQS News Service

1776653  20.11.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1776653&application_name=news&site_id=boersengefluester_html
Visual performance / price development - Cantourage Group SE
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.